These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 21247767)
21. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Tews B; Roerig P; Hartmann C; Hahn M; Felsberg J; Blaschke B; Sabel M; Kunitz A; Toedt G; Neben K; Benner A; von Deimling A; Reifenberger G; Lichter P Oncogene; 2007 Jul; 26(34):5010-6. PubMed ID: 17311001 [TBL] [Abstract][Full Text] [Related]
22. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Scheie D; Andresen PA; Cvancarova M; Bø AS; Helseth E; Skullerud K; Beiske K Am J Surg Pathol; 2006 Jul; 30(7):828-37. PubMed ID: 16819324 [TBL] [Abstract][Full Text] [Related]
23. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236 [TBL] [Abstract][Full Text] [Related]
24. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour]. Born PW; Broholm H; Laursen H Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240 [TBL] [Abstract][Full Text] [Related]
25. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas? Gadji M; Fortin D; Tsanaclis AM; Drouin R Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649 [TBL] [Abstract][Full Text] [Related]
26. Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors. Huang L; Jiang T; Yuan F; Li GL; Liu EZ; Wang ZC Clin Neurol Neurosurg; 2008 Dec; 110(10):1020-4. PubMed ID: 18845382 [TBL] [Abstract][Full Text] [Related]
27. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937 [TBL] [Abstract][Full Text] [Related]
28. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340 [TBL] [Abstract][Full Text] [Related]
29. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848 [TBL] [Abstract][Full Text] [Related]
31. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. Thiessen B; Maguire JA; McNeil K; Huntsman D; Martin MA; Horsman D J Neurooncol; 2003 Sep; 64(3):271-8. PubMed ID: 14558604 [TBL] [Abstract][Full Text] [Related]
32. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Jenkinson MD; du Plessis DG; Smith TS; Joyce KA; Warnke PC; Walker C Brain; 2006 Jul; 129(Pt 7):1884-91. PubMed ID: 16670176 [TBL] [Abstract][Full Text] [Related]
33. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Scheie D; Meling TR; Cvancarova M; Skullerud K; Mørk S; Lote K; Eide TJ; Helseth E; Beiske K Neuro Oncol; 2011 Nov; 13(11):1225-33. PubMed ID: 21856683 [TBL] [Abstract][Full Text] [Related]
34. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028 [TBL] [Abstract][Full Text] [Related]
35. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity. Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026 [TBL] [Abstract][Full Text] [Related]
36. Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms. Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; Kopitzki K; du Plessis DG; Prosser J; Vinjamuri S; Warnke PC Br J Cancer; 2006 Nov; 95(10):1424-31. PubMed ID: 17031404 [TBL] [Abstract][Full Text] [Related]
37. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562 [TBL] [Abstract][Full Text] [Related]
38. Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status? Campbell BA; Horsman DE; Maguire J; Young S; Curman D; Ma R; Thiessen B J Neurooncol; 2008 Aug; 89(1):37-45. PubMed ID: 18458822 [TBL] [Abstract][Full Text] [Related]
39. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279 [TBL] [Abstract][Full Text] [Related]
40. Can morphology predict 1p/19q loss in oligodendroglial tumours? Scheie D; Cvancarova M; Mørk S; Skullerud K; Andresen PA; Benestad I; Helseth E; Meling T; Beiske K Histopathology; 2008 Nov; 53(5):578-87. PubMed ID: 18983467 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]